Member Info for doze

We still await being on https://ec.europa.eu/health/sites/default/files/preparedness_response/docs/covid-19_rat_common-list_en.pdf but now fit for retail sale in the context of the tests usability until 1/1/23 https://www.gov.uk/guidance/using-the-ukca-marking

The Oxford/Cambridge/Wetherby cluster should be OK on its own; keep hands off EU.

The contract with Medusa19 for AffiDX is a 50/50 profit share agreement so margins etc to be delivered.

AVCT have only recently completed a commercial team for diagnostics and I expect the groundwork is being laid for when there are more tests to sell. The leadership team is bigger too and AS is based at Wetherby so more hands on/physical presence/team interaction I imagine than with the therapeutic side.
It has been a 'testing' year for AVCT but I wish them all the best for the new year and a Happy Christmas maybe like most with restraint on mixing . The state covid has reduced us to it is a subdued celebration.

Fingers crossed for a US opening Wiggly. It couldn't have been worse for AS with Brexit and covid gumming up the political works in the EU and UK and the regulators have been exposed for deficient process through imo an entrenched uneven playing field to suit dubious decision takers whose decisions should have been open to debate before actioning. All AS can do is resort to academic lectures to inform decision makers; it was not his fault the playing field favoured the opposition- fleet of foot business with ministerial ear combined with poor science and regulatory process not attuned to pandemics except where 'success' is perceived (astra zeneca vaccine)

The problems with government involvement is the communication of the departments and suggest transparency is required leading to increased efficiency and accountability. Matters such as Innova purchases and ABDX ginolis need to be open to public input and subsequent investment decision making. Post Brexit the country needs to work together not be mutually destructive within its borders.

I have used it to diversify Apre and am up with the new choice though I do think the AVCT adjustment is a nod to a maturing AVCT market which is good. I did not want to use the margin however to up the risk exposure to AVCT.

It is not a priority to get the R rate down because any LFT is unlikely to affect spread of omicron and Boris prefers people stay at work with a false negative test I should imagine as the jabs keep them mobile. I am hopeful for hua in the UK and EU even if only to save the regulators from repercussions of not awarding it.

Or you are an Elon Musk

Will the spreadbet price come in at 114p?

Some insiders could be manipulating the market Bella at this stage of the game. As a long term investor I don't like fretting over short term trades and SP.

https://www.nibsc.org/about_us/mission_and_values.aspx
https://www.nibsc.org/about_us/scientific_advisory_committee.aspx
As our servants it looks like the advisory committee should be pressured to do something about procedures and COBAS 6800/8800 systems perhaps not favourable to the spike protein/whole virus detection with affimer binder/reagent. Can imagine no proactive work here though, just fees taken for advice for MHRA to keep noses clean. They were set up to be a positive force of their own but merged with MHRA on 1/4/13 https://www.nibsc.org/about_us/latest_news/nibsc_merges_with_the_mhra.aspx

https://bioservuk.com/product/avacta-affidx-sars-cov-2-antigen-lateral-flow-test/
tick the boxes to buy. Desk top review needs to be completed at the DHSC for test to be acceptable as proof of covid or not but AffiDX is widely acknowledged by AVCT investors to be the best on the market. https://www.gov.uk/government/publications/covid-19-test-validation-approved-products
The regulators will have a lot of questions to answer if AVCT's test does the job but has been thwarted by procedure.
70% of current sales are on the continent I think I read on here implying 30% in the UK, quantity under wraps

I think I was on the Jura by the look of that post and fro memory but have you listened to this https://www.youtube.com/watch?v=NNp3b_Iv1Gg . Unfortunately I am a grumpy old man, you have to have a survival strategy! I hope the relatively new CEO is not the greedy variety. Compliments of the season.

Thanks for your reply. I am not very quick to action opportunity and wonder whether I should have switched to TEP on its latest dip and then energy prices boosting client numbers as that is another steady player but with a macro boost then. I hope GBG does follow its usual form as Bigtosh says. Compliments of the season to you.

This paper and AS on the North and young scientists; they are on an offensive to persuade Whitehall.

https://www.londonstockexchange.com/news-article/GBG/director-pdmr-shareholding/15248820

Wobbly markets accounting for poor SP but GBG will still be facilitating cashless transactions. Double tops on the charts but GBG missed out on the second so due a recovery I would think.

Perhaps so Neutronic and does category 4 pandemic status facilitate that I wonder.

Since he left gov. employ?